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PERSPECTIVES ON DRUGS 
Injection of synthetic  
cathinones
Synthetic cathinones first appeared on the European illicit 
drug market in 2005. These substances have effects similar 
to known stimulant drugs and are structurally related to 
cathinone, which is found in the Khat plant (Catha edulis). 
Mephedrone is the synthetic cathinone that has received 
particular attention, first appearing as a so-called ‘legal high’ 
on the market in many countries, before European-level 
control measures were introduced in 2010. A number of 
other synthetic cathinones (including pentedrone, methylone, 
MDPV, 4-MEC and N-ethylbuphedrone) are available and used 
on the European drug scene. Many synthetic cathinones have, 
for varying periods of time, been legally available in European 
countries, often sold through physical retail outlets or via 
websites. Ease of availability coupled with relatively low prices 
and high purity compared to street drugs, and popularisation 
via Internet-driven social media, are likely to have contributed 
to current levels of use.
Developing a clear understanding of patterns and levels of 
use of synthetic cathinones in Europe remains a challenge. 
As it is a relatively new phenomenon, existing monitoring 
systems are not geared towards it, no agreed analytic 
laboratory standards exist, and users are seldom aware of 
precisely which substance or combination of substances they 
have used. Furthermore purchasing on the Internet enables 
users to remain discreet and thus a much hidden population. 
Important insights have been collected for this analysis, 
however, from a limited number of national and targeted 
surveys, data presented in Reitox national reports and the 
scientific literature.
Over 80 synthetic cathinone derivatives 
were detected via the EU Early Warning 
System (EU–EWS) between 2005 
and 2014. This analysis explores new 
worrying localised and national outbreaks 
of injecting these substances and 
recommends close monitoring of the issue 
as a public health priority.
Against a backdrop of an overall decline 
in the injecting of illicit drugs in Europe, 
recent reports of the injection of new 
psychoactive substances (NPS), in 
particular synthetic cathinones, have 
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Available evidence suggests that in most countries the use of 
synthetic cathinones in the general population remains low, 
and the limited number of countries that have included either 
mephedrone or other synthetic cathinones in recent general 
population surveys (1) indicate a last year prevalence rate of 
1 % or less among adults. However, there are other groups 
where higher prevalence levels of synthetic cathinone use are 
reported, such as clubbers, high-risk drug users and treatment 
entrants. For example, targeted studies of mephedrone use 
among samples of young European clubbers report last-year 
prevalence levels of between 1 % and 14 % (2). In addition, 
Public Health England (2013) reported the number of clients 
aged 18 years or over entering treatment for mephedrone use 
increased between 2011/12 and 2012/13 from 900 to 1630.
While most cathinone use involves either snorting the drugs 
as a powder or oral use, a recent worrying phenomenon has 
emerged of synthetic cathinones being injected by some 
groups of drug users. On the whole, reports suggest that 
injecting cathinone users are primarily injectors of other drugs 
(heroin, amphetamines) who, for a variety of reasons, switch to 
cathinone injection or include cathinones in their drug-using 
repertoire. In addition, there are reports of long-term abstinent 
ex-opiate users who have started to inject cathinones (Rácz 
et al., 2014; Daly, 2012; Van Hout and Bingham, 2012), and 
limited reports of young people beginning their injecting 
career with cathinones (Daly, 2012; Austrian Reitox national 
focal point, 2013).
In some European countries the injection of synthetic 
cathinones is reported to be a relatively low-level and localised 
phenomenon, restricted to particular groups of high-risk drug 
users (Austria, Belgium, the Czech Republic, France, Germany, 
Ireland, Poland, Spain and the United Kingdom). In Hungary 
and Romania, however, a more substantial level of use of 
synthetic cathinones injection has been identified among 
large cohorts of high-risk drug users. 
I  Synthetic cathinone injection: two countries with widespread use among high-risk users
In both Hungary and Romania, acute shortages in the 
availability of heroin in 2010 and 2011, along with the 
increased availability of cathinones sold as ‘legal highs’ 
in physical retail outlets in Romania and in online shops 
in Hungary, have played a role in the development of a 
generalised level of synthetic cathinones injection among 
existing cohorts of high-risk drug users. In Hungary, the use 
of synthetic cathinones mainly among heroin injectors has 
been documented by needle and syringe programmes, which 
reported that by 2013 some 58 % of programme clients 
nationwide were injecting cathinones as their primary drug 
(Hungarian national focal point, 2014). After almost pushing 
Analysis of seized injecting equipment (needle, syringe, filter, 
spoon) in Hungary (3)
Source: Hungarian national focal point, 2014.
 
heroin out of the market, synthetic cathinones also began 
to displace amphetamines. It is interesting to note that the 
cathinone of choice changed over time in a way that appears 
to be directly linked with availability — when one cathinone 
was controlled, it was quickly replaced by a cathinone that 
was not controlled (see figure).
Hungarian opioid substitution programmes also reported 
in 2012 that between 10–50 % of their clients were using 
synthetic cathinones. The percentage of primary synthetic 
cathinone users entering specialised drug treatment for the 
first time, although not systematically monitored in Hungary, 
has been estimated at just under 20 % in 2012 (Péterfi et al., 
2014). 
Romania has also recorded a rapid spread in availability and 
use of synthetic cathinones and other new psychoactive 
substances, originally made widely available through 
physical retail outlets (known as ‘dream shops’). A needle 
and syringe programme in Bucharest, for example, reported 
in 2012 that of 1 326 surveyed clients, 51 % injected new 
psychoactive substances (mainly synthetic cathinones), 44 % 
injected heroin and 5 % injected both NPS and heroin. Data 
on clients entering specialised drug treatment in Romania 
in 2012 showed that a third (33 %) of clients reported new 
psychoactive substances as their primary drug. However, 
2013 has seen a drop in the number injecting cathinones, 
with only 18 % of clients being NPS users entering treatment. 
Other indicators (e.g. emergency room admissions, drug 
related deaths) seem to confirm this decrease.
 
(1) Czech Republic, Spain, Malta, Slovenia, Slovakia, Poland, Portugal and the United Kingdom.  
(2) The known minimum and maximum are 0.9 % (Flemish study) and 13.8 % (UK study). 
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I  More limited or localised reports of synthetic cathinones injection
More localised outbreaks of cathinones injection have been 
identified in several countries, typically involving high-risk 
drug users in contact with low-threshold facilities, psychiatric 
facilities, and drug treatment centres. 
In France, a recent study has developed a scientific approach 
to obtain information through the chemical analysis of 
residues in syringes (Néfau et al., 2015). In total, 3 489 
syringes were collected from 17 sites in Paris where syringe 
retrieval devices are located. The analysis results showed 
that 23 % of the syringes contained 4-methylethylcathinone. 
The appearance of this cathinone and its growing presence 
in the syringes was observed between summer and winter 
2012, mainly at sites where cocaine was the most previously 
injected drugs.
A 2011 study of Irish prisoners showed that this population 
reported injecting cathinones. It found that a last year 
prevalence of injection of mephedrone  was 13 % among 
females and 2 % among males. The respective figures for 
methylone were 7 % and 1 % (Drummond, et al. 2014). 
Data from a 2012 needle and syringe programme survey in 
Ireland reported that over 6 % of the participants had used 
mephedrone in the past month, and of these 95 % had 
injected it. In addition, several in-depth qualitative studies 
that confirm the presence of mephedrone injection have been 
conducted in Dublin (e.g. Van Hout and Bingham, 2012).
In Austria a small 2010 survey among drug treatment clients 
in Graz (n=27) identified that just under 60 % of surveyed 
mephedrone users reported injecting the drug. The reported 
frequency of use was relatively intensive among this group, 
with 50 doses of the drug per week on average, and a third 
of respondents reporting that mephedrone was the drug 
causing them the most problems. Both older polydrug users 
and younger users without previous opioid experience were 
represented among these users (Austrian Reitox national 
focal point, 2013). At present, mephedrone appears to be 
declining in Austria (Austrian Reitox national focal point, 
2014).
Mephedrone injection has also been reported in the United 
Kingdom, based on law enforcement reports (Chadd, 2013), 
although the evidence of increased mephedrone injection 
in the study location (South Wales) was mainly anecdotal. 
In addition, the national Druglink Street Drug Trends 2012 
survey in the UK reported on mephedrone users who were 
experiencing multiple harms and making contact with drug 
services. These included both experienced users of other 
drugs switching to mephedrone, and novice users who 
have never injected other drugs before. Some users were 
mixing mephedrone with heroin, in a ‘speedball’ type of 
use. Mephedrone users were reportedly younger than other 
groups of high-risk drug users seen by drug services. In 
2013, the Unlinked Anonymous Monitoring Survey of people 
who inject drugs in contact with services found that during 
the preceding year 8 % of the participants had injected 
mephedrone (Public Health England, 2014; Health Protection 
Scotland, Public Health Wales, and Public Health Agency 
Northern Ireland, 2014).
A recent survey among Spanish harm reduction centre 
clients in Barcelona highlighted the injecting use of the 
synthetic cathinone 4-MEC among their population. In this 
study, 46 % of clients reported lifetime consumption of any 
new psychoactive substance (most often 4-MEC), mostly in 
combination with heroin, and half of users had injected the 
I  Facts and figures 
Synthetic cathinones encompass a wide group of 
substances that are synthetic derivatives of cathinone, 
which is naturally present in the Khat (Catha edulis) plant. 
They include mephedrone, pentedrone, methylone, MDPV 
and 4-MEC. See the EMCDDA drug profile on synthetic 
cathinones.
Street names for synthetic cathinones vary by country 
and include Miaow Miaow, M-Cat, Msmack, Drone, Fert, 
Bubbles (in English-speaking countries), Kati, Pentakristály 
(in Hungary), and Funky, Cocolino, El Padrino and Magico 
(in the Czech Republic).
Synthetic cathinones mainly appear on the drug markets 
as powders and tablets. 
Between 2005 and 2014 more than 81 synthetic 
cathinone derivatives were reported to the EU Early 
Warning System (see interactive element online).
Methcathinone was first developed in the 1930s as an 
antidepressant. Since then it has been used illicitly in the 
former Soviet Union countries and Poland (4). 
In Israel, the use of khat-extracted cathinones spread in 
the early 2000s. These substances were banned in 2004; 
further derivatives were banned in 2010.
Synthetic cathinones were first seized in Europe in 2005 
(methylone in the Netherlands).
In 2010 mephedrone was submitted to control measures 
in the European Union.
(4) Bretteville-Jensen et al., 2013 provide an account of the history of synthetic cathinones.
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NPS. Analysis of urine samples also identified recent 4-MEC 
use in almost 20 % of the tested samples (Aranda et al., 
2014).
A similar study at city level was carried out in Finland in the 
Helsinki area. Of a sample of 100 ‘marginalised drug users’, 
54 reported using MDPV in the past year and of these 96 % 
had injected the drug (Tammi et al., 2011).
There is additional limited data on the use of cathinones or 
more generally of NPS by people who inject drugs, but where 
the route of administration is non-specified or unknown. 
For example, survey data from low-threshold programme 
clients in the Czech Republic in 2012, of whom 95 % were 
injectors, found 10.5 % had used a new synthetic drug in the 
last year. In 2013, about one third of high risk drug users in 
Prague – who are mostly injectors – (4,800) were estimated 
to have used new synthetic drugs likely containing synthetic 
cathinones (such as Funky and El Magico) in the last 12 
months, however just few (approximately 2 %) have reported 
synthetic cathinones as primary drug (Czech national focal 
point, 2015). Similarly, a 2012 survey of clients at needle 
and syringe programmes in Poland found that 15 % of clients 
reported ‘new psychoactive drugs’ as their most problematic 
substance, while 12 % had used mephedrone in the month 
preceding the survey (and 14 % had used other NPS).
In the Swedish city of Västerås, an increase in the number of 
cases of stimulant-related intoxications requiring admission 
to the hospital emergency department fuelled further 
investigation of this phenomenon. This revealed that 76 % 
of cases were related to the use of the cathinone MDPV and 
95 % occurred among chronic drug users who were often 
hepatitis C virus (HCV) positive, signalling drug injection 
(Lindeman et al., 2012).
I  Cathinones injecting among men who have sex with men (MSM) 
There is increasing concern about the emergence of a 
new trend among some sub-groups of gay men involving 
the injection of illicit drugs, including cathinones and 
methamphetamine, in a practice known as ‘slamming’. This 
usually takes place at ‘chem sex’ parties (Bourne et al., 
2014) where mephedrone is typically used in parallel or in 
combination with other drugs such as methamphetamine 
(London), GHB/GBL, cocaine (France) and sildenafil (‘Viagra’) 
to enhance sexual experiences. Parties can last from around 
eight hours up to three days (Spire et al., 2013) with the 
participants frequently engaging in risky sexual practices such 
as not using condoms and sharing multiple partners (Stuart, 
2013). Consequently, this form of use is associated with a 
highly elevated risk of the spread of blood-borne and sexually 
transmitted diseases. In London, data from Antidote, a 
specialist drug clinic targeting services at the gay community, 
showed that 75 % of clients using mephedrone were doing 
so solely to facilitate sex, with 80 % injecting it. Of these 
users, 75 % reported being human immunodeficiency virus 
(HIV) positive and 70 % reported sharing needles. To date in 
Europe, this new practice has primarily been documented 
among restricted sub-groups of gay men in London and a 
small number of French cities (Lahaie et al., 2013); however, 
the potential exists, in this highly mobile population, for it to 
become more widespread. 
I  Conclusions
This analysis has documented emerging evidence of 
new patterns of synthetic cathinone injection amongst 
subpopulations of drug users in Europe. There is concern about 
the addictive potential of these drugs and associated physical 
and mental health harms experienced by users (see ‘Health 
consequences’), and about the high-risk behaviours associated 
with injection of these substances. While at present there 
are no specific interventions targeted at synthetic cathinones 
users, given that, for several researched synthetic cathinones, 
there appear to be similar mechanisms of action, effects and 
harms as for amphetamines, interventions with evidence of 
effectiveness for these drugs may prove useful (EMCDDA, 
2014). Bearing in mind the serious potential impact of new 
patterns of injection being identified, the close monitoring of 
synthetic cathinones use in Europe is clearly an important 
public health priority.
I  Interactive element
Interactive element on demystifying the chemistry available on the EMCDDA 
website: www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection
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Synthetic cathinones have been linked to a range of health 
problems for users (Miotto et al., 2013). The drugs toxicity 
at high doses, which is similar to that of cocaine, MDMA 
and amphetamines (Dargan and Wood, 2013), has resulted 
in emergency room presentations across Europe; deaths 
involving synthetic cathinones do occur (Wood and Dargan, 
2012; Corkery et al., 2012).  
 
Injecting synthetic cathinones use has been associated with 
a high frequency of injection for several of the substances, 
with European injectors of synthetic cathinones reporting a 
number of injection-related and other complications. These 
include an intense burning sensation at the injection site, 
with repetitive injection resulting in skin erosion, localised 
infections, blisters, spots, abscesses, gangrenous tissue, 
blood clots, permanent numbness and spasms. In addition, 
some problems associated with synthetic cathinones 
injection and the spread of infectious diseases have 
been highlighted. In Hungary, possible increases in HCV 
infection were observed in synthetic cathinones injectors 
and associated with high frequency of injection (for some 
cathinones 11.5 times a day on average, Horvath, 2013). In 
Romania the high frequency of injecting these drugs (6–8 
times per day according to local studies), coupled with a 
reduction in the availability of sterile injecting equipment, 
are cited as factors playing a role in the recent HIV outbreak 
(Botescu et al., 2012).  
 
In addition to injection-related risks, cathinones use has 
also been associated with risky sexual practices (Van Hout 
and Brennan, 2011a; Stuart, 2013; Spire et al., 2013). In 
addition to reports of ‘slamming’ parties in sub-populations 
of MSM in London and French cities, a qualitative study of 
mephedrone users in Ireland reported that use of the drug 
even in non-injecting recreational users was linked to sexual 
encounters involving multiple partners and a lack of condom 
use (Van Hout and Brennan, 2011b). 
 
The psychological side-effects of synthetic cathinones can 
include a difficult ‘comedown’, depression, anxiety, panic 
attacks, paranoia and psychosis. Compulsive use and 
dependence symptoms have been reported by synthetic 
cathinone users. These include strong cravings, relatively 
rapid development of tolerance and prolonged binges, 
sometimes lasting for many days. The compulsive nature 
of use might stem from the fact that the effects of several 
of these drugs are in general short-lived, with a maximum 
of 2–4 hours at oral administration (Corkery et al., 2012; 
Miotto, 2013; EMCDDA, 2010). A study of psychiatric 
inpatient facilities in Germany (Livak et al., 2013) 
reported on patient admissions presenting with synthetic 
cathinones-related psychotic symptoms. Psychotic states 
following mephedrone use often persisted for several 
days despite the administration of neuroleptic medication. 
Most of these cases were polydrug users who had often 
used injection as a route of administration for cathinones. 
Hungary has also reported high levels of psychiatric 
comorbidity associated with cathinone use, in addition to 
factors such as acute psychosis, violence and decrease in 
treatment compliance among this patient group (Hungarian 
Reitox national focal point, 2013, Szily and Bitter, 2013, 
Rácz and Bodrogi, 2014). 
 
Health consequences associated with use and injection of synthetic cathinones 
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